Close Menu

NEW YORK (GenomeWeb) – Exact Sciences reported after the close of the market on Tuesday that its third quarter revenues rose 63 percent year over year thanks to a 49 percent increase in testing volumes for its Cologuard colorectal cancer screening test.

For the three months ended Sept. 30, the Madison, Wisconsin-based molecular diagnostics company reported revenues of $118.3 million, up from revenues of $72.6 million a year earlier and beating the analysts' average estimate of $109.3 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.